Long-Term Cost-Effectiveness Analyses of Empagliflozin Versus Oral Semaglutide, in Addition to Metformin, for the Treatment of Type 2 Diabetes in the UK
Crossref DOI link: https://doi.org/10.1007/s13300-020-00883-1
Published Online: 2020-07-22
Published Print: 2020-09
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Ramos, Mafalda
Cummings, Michael H.
Ustyugova, Anastasia
Raza, Syed I.
de Silva, Shamika U.
Lamotte, Mark
Text and Data Mining valid from 2020-07-22
Version of Record valid from 2020-07-22
Article History
Received: 5 June 2020
First Online: 22 July 2020